Results 151 to 160 of about 42,521 (302)
Diabetic Peripheral Neuropathy: Molecular Staging, Risk Factors, Therapeutics, and Emerging Trends
The heterogeneous landscape of DPN can be unified through a tripartite pathogenic model encompassing progressive stages of metabolic dysregulation, chronic inflammation, and overt neuronal damage. Within this framework, six clinical subtypes were identified, namely, hyperglycemia‐driven, dyslipidemia‐driven, inflammation‐driven, dysvascularity‐driven ...
Xiaofeng Dai, Mingze Tang
wiley +1 more source
Fang et al. demonstrate a significant causal relationship among gut microbiota, gut metabolites, and diabetic complications, highlighting a biological link underlying mechanisms of diabetic vascular diseases. These findings provide important implications for future therapeutic strategy and risk prediction.
Jiaxi Fang +6 more
wiley +1 more source
ABSTRACT The growing recognition of the microbiome's role in human health has propelled the emergence of microbiota medicine—a new discipline integrating microbiology, multi‐omics, and clinical science. Advances in sequencing, data integration, and interventions such as fecal microbiota transplantation (FMT) have transitioned the field from ...
Min Dai +6 more
wiley +1 more source
Abstract Background Esophagectomy causes anatomical changes that can lead to rapid food transit and reactive hypoglycemia (RH). Patients are advised on eating patterns postesophagectomy to prevent RH, but its true incidence and the impact of dietary recommendations remain under‐researched.
Rachel O'Kelly +9 more
wiley +1 more source
A case report on the long‐term use of teduglutide in a pediatric patient with short bowel syndrome
Abstract Short bowel syndrome (SBS) is the leading cause of intestinal failure, frequently necessitating long‐term parenteral nutrition (PN). Teduglutide (TED), a glucagon‐like peptide‐2 analog, has demonstrated efficacy in reducing PN dependence in both adults and children. However, long‐term data in pediatric populations remain limited.
Tsuyoshi Sakurai +8 more
wiley +1 more source
Abstract Background A randomized, double‐blind, placebo‐controlled trial was conducted to evaluate efficacy and safety of glepaglutide in patients who have short bowel syndrome with intestinal failure (SBS‐IF). At the end of the trial, exit interviews were conducted to explore participants' experiences and to assess the impact of the disease and ...
David F. Mercer +5 more
wiley +1 more source
GLP‐1 Receptor Agonists for Obstructive Sleep Apnea: An Otolaryngologist's Prescription?
The Laryngoscope, EarlyView.
Alina Zgardau +3 more
wiley +1 more source
Endoscopic small bowel therapies for type 2 diabetes
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel +4 more
wiley +1 more source
What Are the Impacts of GLP‐1 Drugs in Patients Needing Head/Neck Surgery?
The Laryngoscope, EarlyView.
Chelsea Gelboin‐Burkhart +3 more
wiley +1 more source
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu +13 more
wiley +1 more source

